News

ERDERA - 2025 Call on pre-clinical therapy studies for rare diseases open

Published on | 1 year ago

Programmes Health

The European Partnership on Rare Diseases (ERDERA) has opened its first Joint Transnational Call for Proposals on 'Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation'. The timeline of the call is as follows:

  • Pre-proposal Submission Deadline: 13 February 2025
  • Full Proposal Invitations: Early May 2025
  • Funding Decisions: December 2025


Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on who can apply & how is specified in the call documents. Questions? Please contact europe@fwo.be .

Projects should address at least two of the following:

  • Development of novel therapies in a pre-clinical setting.
  • Creation and validation of predictive and pharmacodynamic biomarkers.
  • Replication of pre-clinical findings to enhance reliability.
  • Pre-clinical proof-of-concept studies for therapy readiness.

Please note, certain approaches, including ATMP therapies and clinical trials, are excluded from this call. Detailed eligibility criteria are outlined in the Call Guidelines.

More information is available on the ERDERA website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1784 articles available search in articles 

Testimonial

SAPHIRe - Securing the Adoption of Personalised Medicin in Regions

The Department of Economy, Science and Innovation of the Flemish government coordinates the Horizon 2020 Coordination and Support Action SAPHIRe, which started on 1 December 2018. The aim of the project is to secure the adoption of personalised medicine in all European regions, including sparsely populated and remote regions and regions with different innovation capacities. 

The activities of SAPHIRe are complementary to the smart specialisation partnership on personalised medicine – S3P4PM, which is also coordinated by the Department of Economy, Science and Innovation.